Locally advanced NSCLC, age <60 years, non-squamous cell lung cancer, bulky mediastinal lymphadenopathy, genetic mutations of programmed cell death 1 (PD-1) protein, liver kinase B1 (LKB1) protein, Kirsten rat sarcoma viral oncogene (KRAS), epidermal growth factor receptor (EGFR), or rearrangements of anaplastic lymphoma kinase (ALK) portend a worse prognosis [5]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.